Australija - anglų - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 1.09 mg (equivalent: topotecan, qty 1 mg) - injection, concentrated - excipient ingredients: tartaric acid; hydrochloric acid; sodium hydroxide; water for injections - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 4.346 mg (equivalent: topotecan, qty 4 mg) - injection, concentrated - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; tartaric acid - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

medi-physics inc. dba ge healthcare. - indium in-111 oxyquinoline (unii: lgx9ol562t) (indium cation in-111 - unii:wjz06c0h8l) - indium cation in-111 1 ug in 1 ml - indium in 111 oxyquinoline solution is indicated for radiolabeling autologous leukocytes. indium in 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. the degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. indium in 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. if localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. if localization or diagnosis by these methods fails or is ambiguous, indium in 111 oxyquinoline labeled leukocyte imaging may be appropriate. none known.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; hydrochloric acid; sodium hydroxide; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Singapūras - anglų - HSA (Health Sciences Authority)

merz asia pacific pte. ltd. - clostridium botulinum neurotoxin type a (150 kda), free from complexing proteins - injection, powder, for solution - 100 ld50 units - clostridium botulinum neurotoxin type a (150 kda), free from complexing proteins 100 ld50 units

Singapūras - anglų - HSA (Health Sciences Authority)

merz asia pacific pte. ltd. - clostridium botulinum neurotoxin type a (150 kda), free from complexing proteins - injection, powder, for solution - 50 ld50 units - clostridium botulinum neurotoxin type a (150 kda), free from complexing proteins 50 ld50 units

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

anazaohealth corporation - indium in-111 oxyquinoline (unii: lgx9ol562t) (indium in-111 oxyquinoline - unii:lgx9ol562t) - indium in-111 oxyquinoline 2 mci in 1 ml - this preparation is supplied as a sterile, non-pyrogenic, isotonic aqueous solution with a ph range of 6.5 to 7.5 and is not for direct injection. each milliliter contains 2 mci at calibration time, 50μg oxyquinoline, 100μg polysorbate 80, and 6 mg of hepes (n-2-hydroxyethyl-piperazine-n’-2-ethane sulfonic acid) buffer in 0.75% sodium chloride solution. it is intended for single use only and contains no bacteriostatic agent.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

bwxt medical ltd. - indium in-111 oxyquinoline (unii: lgx9ol562t) (indium cation in-111 - unii:wjz06c0h8l) - indium in 111 oxyquinoline is indicated for radiolabeling autologous leukocytes. indium in 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. the degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. indium in 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. if localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. if localization or diagnosis by these methods fails or